BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mehyar N, Mashhour A, Islam I, Alhadrami HA, Tolah AM, Alghanem B, Alkhaldi S, Somaie BA, Al Ghobain M, Alobaida Y, Alaskar AS, Boudjelal M. Discovery of Zafirlukast as a novel SARS-CoV-2 helicase inhibitor using in silico modelling and a FRET-based assay. SAR QSAR Environ Res 2021;32:963-83. [PMID: 34818959 DOI: 10.1080/1062936X.2021.1993995] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Mohammad TSH, Gupta Y, Reidl CT, Nicolaescu V, Gula H, Durvasula R, Kempaiah P, Becker DP. In Silico Binding of 2-Aminocyclobutanones to SARS-CoV-2 Nsp13 Helicase and Demonstration of Antiviral Activity. IJMS 2023;24:5120. [DOI: 10.3390/ijms24065120] [Reference Citation Analysis]
2 Halma MTJ, Wever MJA, Abeln S, Roche D, Wuite GJL. Therapeutic potential of compounds targeting SARS-CoV-2 helicase. Front Chem 2022;10:1062352. [PMID: 36561139 DOI: 10.3389/fchem.2022.1062352] [Reference Citation Analysis]
3 Ghobain MA, Rebh F, Saad A, Khan AH, Mehyar N, Mashhour A, Islam I, Alobaida Y, Alaskar AS, Boudjelal M, Jeraisy MA. The efficacy of Zafirlukast as a SARS-CoV-2 helicase inhibitor in adult patients with moderate COVID-19 Pneumonia (pilot randomized clinical trial). J Infect Public Health 2022;15:1546-50. [PMID: 36436481 DOI: 10.1016/j.jiph.2022.11.016] [Reference Citation Analysis]
4 Lazniewski M, Dermawan D, Hidayat S, Muchtaridi M, Dawson WK, Plewczynski D. Drug repurposing for identification of potential spike inhibitors for SARS-CoV-2 using molecular docking and molecular dynamics simulations. Methods 2022;203:498-510. [PMID: 35167916 DOI: 10.1016/j.ymeth.2022.02.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]